Asana BioSciences, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asana BioSciences, LLC
Leo Pharma Strengthens Dermatology Position With Second Eczema Win
The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.
Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp
Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.
JT Gains World-First Topical JAK Inhibitor Approval
Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.
First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis
Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.